

Joint Modern Slavery Act

Annual Report 2023

for

Searchlight Pharma Inc.

and its subsidiary

Aralez Pharmaceuticals Canada Inc.

SEARCHLIGHT
PHARMA

Aralez
Pharmaceuticals

1. INTRODUCTION


This report (“Report”) is jointly submitted by Searchlight Pharma Inc. (“Searchlight”) and its wholly owned subsidiary, Aralez Pharmaceuticals Canada Inc. (“Aralez”) (collectively, “we”, “us”, “our”), and is made pursuant to section 11 of the *Fighting Against Forced Labour and Child Labour in Supply Chains Act* (“Act”) for our financial year ended December 31, 2023. This Report has been prepared and will be provided to the shareholders of Searchlight together with its annual financial statements, in accordance with section 13(2) of the Act.

We neither endorse nor tolerate any form of modern slavery in our activities and supply chains, including but not limited to forced labour and child labour, as defined in section 2 of the Act. We hold ourselves to the highest standards and expect the same of our employees, contractors, suppliers and partners.

2. CORPORATE STRUCTURE, ACTIVITIES and SUPPLY CHAINS

Structure

Searchlight is a Canadian-based specialty healthcare company that is headquartered in Montreal, Québec and is incorporated under the *Canada Business Corporations Act*. Aralez is headquartered in Mississauga, Ontario and is incorporated under the *Ontario Business Corporations Act*. A schematic representation of our corporate structure can be found below.



Activities

We hold a diversified portfolio of specialized pharmaceutical and healthcare products. Our main business operations include acquisition, in-licensing and commercialization of innovative and unique specialty healthcare products. In doing so, we place great emphasis and value on forming business arrangements with reputable companies with the aim to provide safe and effective pharmaceutical and healthcare products to the Canadian market.

Until the closure of its manufacturing facility in Varennes, Québec in Q2 of 2023, Aralez was also engaged in the manufacture of pharmaceutical products for sale and distribution in Canada and in certain other markets around the world.

Supply Chains

The components of the products that we distribute and sell in Canada are manufactured by a network of reputable external contract manufacturing organizations located in the following

Searchlight Pharma Inc.

1600 Rue Notre-Dame Ouest, Suite 312, Montréal, Québec, Canada H3J 1M1
t. 514-613-1513 / f. 1-855-221-2116 www.searchlightpharma.com

Aralez Pharmaceuticals Canada Inc.

6733 Mississauga Road, Suite 800, Mississauga, Ontario, Canada L5N 6J5
t. 905-673-6980

countries: Belgium, Canada, France, Germany, Hungary, India, Ireland, Israel, Italy, Japan, Netherlands, Spain, Switzerland, United Kingdom and the United States of America.

3. POLICIES and DUE DILIGENCE PROCESSES

Our code of conduct and related policies guide employees on the principles and standards expected around ethics, integrity and compliance, including how to report concerns.

4. FORCED LABOUR and CHILD LABOUR RISKS

We have not started the process of identifying risks with respect to forced labour or child labour in our supply chains and activities. As such, we have not taken steps to assess or manage the risk of forced and child labour in our supply chains and activities.

5. REMEDIATION MEASURES

We have not identified any forced labour or child labour in our activities and supply chains and have taken no remediation measures.

6. REMEDIATION OF LOSS OF INCOME

We have not identified any loss of income to the most vulnerable families resulting from any measure taken to eliminate the use of child or forced labour in our activities and supply chains. Therefore, we have not undertaken steps to remediate any such loss of income.

7. TRAINING

We currently do not have training relating to forced and child labour; however, our code of conduct exemplifies our commitment to compliance with legislation governing health and safety standards, anti-discrimination and workplace safety, all of which informs our responsible sourcing.

8. ASSESSING EFFECTIVENESS

We have not yet begun the process of identifying risks of forced and child labour in our activities and supply chains. As such, we have not yet taken any measures to assess or manage any forced labour or child labour in our activities and supply chains.

9. FUTURE PLANS: DUE DILIGENCE PROCESSES, POLICIES and TRAINING

Over the next two years, we plan to conduct mapping activities and risk assessments of child and forced labour in our activities and supply chains. We also plan to develop and enforce a Supplier Code of Conduct requiring our suppliers to, among other things, abide by applicable employment standards, labour and human rights legislation. Our supplier agreement templates will include anti-forced and anti-child labour clauses.

Searchlight Pharma Inc.

1600 Rue Notre-Dame Ouest, Suite 312, Montréal, Québec, Canada H3J 1M1
t. 514-613-1513 / f. 1-855-221-2116 www.searchlightpharma.com

Aralez Pharmaceuticals Canada Inc.

6733 Mississauga Road, Suite 800, Mississauga, Ontario, Canada L5N 6J5
t. 905-673-6980


Further, we plan to write policies, standard operating procedures and implement training on forced and child labour for all of our employees. The training will communicate our position that modern slavery, including forced labour and child labour as defined in the Act, is not tolerated by us and will include guidance on what an employee should do if they become aware of any such instances while engaged with a supply partner.

10. APPROVAL and ATTESTATION

This Report was approved pursuant to subparagraph 11(4)(b)(ii) of the Act by the board of directors of Searchlight Pharma Inc. on May 27, 2024.

In accordance with the requirements of the Act, and in particular section 11 thereof, I attest that I have reviewed the information contained in the Report for the entities listed above. Based on my knowledge, and having exercised reasonable diligence, I attest that the information in the report is true, accurate and complete in all material respects for the purposes of the Act, for the reporting year listed above.

I have the authority to bind Searchlight Pharma Inc. and Aralez Pharmaceuticals Canada Inc.

By  _____
Name: Mark Nawacki
Title: President & CEO, Director